- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06989112
- Juicio original
Destiny-endometrial01: un estudio de fase III de trastuzumab deruxtecan más rilvegostomig o pembrolizumab como tratamiento de primera línea de la primera línea de HER2 (IHC 3+/2+), competencia de reparación de desajuste (PMMR) endometrial cáncer de cáncer endometrial (PMMR). (DE-01)
Destiny-endometrial01: un estudio de fase III de fase III de trastuzumab derutepan (t-dxd) más cegado, aleatorizado, multicéntrico, de fase III de trastuzumab deruxtecan (T-DXD) más rilvegostomig o pembrolizumab vs quimioterapia más pembrolizumab como primera línea de terapia de Her2-expresión (IHC 3+/2+), MISMAT (PMMR), cáncer de endometrial avanzado primario o recurrente
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: AstraZeneca Clinical Study Information Center
- Número de teléfono: 1-877-240-9479
- Correo electrónico: information.center@astrazeneca.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 13353
- Reclutamiento
- Research Site
-
Chemnitz, Alemania, 09116
- Aún no reclutando
- Research Site
-
Dessau, Alemania, 06847
- Reclutamiento
- Research Site
-
Dresden, Alemania, 01307
- Reclutamiento
- Research Site
-
Düsseldorf, Alemania, 40225
- Aún no reclutando
- Research Site
-
Essen, Alemania, 45147
- Reclutamiento
- Research Site
-
Hamburg, Alemania, 20246
- Reclutamiento
- Research Site
-
Kassel, Alemania, 34125
- Reclutamiento
- Research Site
-
Kiel, Alemania, 24105
- Aún no reclutando
- Research Site
-
Leipzig, Alemania, 04103
- Reclutamiento
- Research Site
-
Mannheim, Alemania, 68167
- Aún no reclutando
- Research Site
-
Marburg, Alemania, 35043
- Retirado
- Research Site
-
München, Alemania, 80637
- Aún no reclutando
- Research Site
-
Münster, Alemania, 48149
- Aún no reclutando
- Research Site
-
Saarbrücken, Alemania, 66113
- Reclutamiento
- Research Site
-
-
-
-
-
Blacktown, Australia, 2148
- Reclutamiento
- Research Site
-
East Melbourne, Australia, 3002
- Terminado
- Research Site
-
Nedlands, Australia, 6009
- Reclutamiento
- Research Site
-
South Brisbane, Australia, 4101
- Reclutamiento
- Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Aún no reclutando
- Research Site
-
Linz, Austria, 4021
- Aún no reclutando
- Research Site
-
Vienna, Austria, 1090
- Aún no reclutando
- Research Site
-
Wein, Austria, 1130
- Reclutamiento
- Research Site
-
-
-
-
-
Barretos, Brasil, 14784-057
- Reclutamiento
- Research Site
-
Belo Horizonte, Brasil, 30130 100
- Reclutamiento
- Research Site
-
Goiânia, Brasil, 74000-000
- Reclutamiento
- Research Site
-
Londrina, Brasil, 86015-520
- Reclutamiento
- Research Site
-
Porto Alegre, Brasil, 90020-090
- Reclutamiento
- Research Site
-
Porto Alegre, Brasil, 90610000
- Reclutamiento
- Research Site
-
Rio de Janeiro, Brasil, 20220-410
- Reclutamiento
- Research Site
-
Salvador, Brasil, 41.950-610
- Reclutamiento
- Research Site
-
São Paulo, Brasil, 01246-000
- Reclutamiento
- Research Site
-
São Paulo, Brasil, 01317-001
- Reclutamiento
- Research Site
-
São Paulo, Brasil, 1409
- Reclutamiento
- Research Site
-
Teresina, Brasil, 64049-200
- Reclutamiento
- Research Site
-
-
-
-
-
Anderlecht, Bélgica, 1070
- Reclutamiento
- Research Site
-
Brussels, Bélgica, 1200
- Reclutamiento
- Research Site
-
Charleroi, Bélgica, 6060
- Retirado
- Research Site
-
Ghent, Bélgica, 9000
- Reclutamiento
- Research Site
-
Leuven, Bélgica, 3000
- Reclutamiento
- Research Site
-
Liège, Bélgica, 4000
- Reclutamiento
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Reclutamiento
- Research Site
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Reclutamiento
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Retirado
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 2Y9
- Retirado
- Research Site
-
-
Ontario
-
London, Ontario, Canadá, N6A 4L6
- Reclutamiento
- Research Site
-
Toronto, Ontario, Canadá, M4N 3M5
- Reclutamiento
- Research Site
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Aún no reclutando
- Research Site
-
Montreal, Quebec, Canadá, H1T 2M4
- Reclutamiento
- Research Site
-
Montreal, Quebec, Canadá, H2X 0A9
- Reclutamiento
- Research Site
-
Montreal, Quebec, Canadá, H3G 1A4
- Reclutamiento
- Research Site
-
Québec, Quebec, Canadá, G1J 1Z4
- Reclutamiento
- Research Site
-
-
-
-
-
Goyang-si, Corea del Sur, 10408
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 03080
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Research Site
-
Suwon, Corea del Sur, 16499
- Reclutamiento
- Research Site
-
-
-
-
-
Aalborg, Dinamarca, 9100
- Reclutamiento
- Research Site
-
Herlev, Dinamarca, 2730
- Retirado
- Research Site
-
København Ø, Dinamarca, 2100
- Reclutamiento
- Research Site
-
Odense, Dinamarca, 5000
- Reclutamiento
- Research Site
-
-
-
-
-
A Coruña, España, 15009
- Reclutamiento
- Research Site
-
Córdoba, España, 14004
- Reclutamiento
- Research Site
-
Donostia / San Sebastian, España, 20014
- Reclutamiento
- Research Site
-
El Palmar, España, 30120
- Reclutamiento
- Research Site
-
L'Hospitalet de Llobregat, España, 08908
- Reclutamiento
- Research Site
-
Madrid, España, 28034
- Reclutamiento
- Research Site
-
Madrid, España, 28041
- Reclutamiento
- Research Site
-
Palma de Mallorca, España, 07010
- Aún no reclutando
- Research Site
-
Valencia, España, 46009
- Reclutamiento
- Research Site
-
Valencia, España, 46006
- Reclutamiento
- Research Site
-
Zaragoza, España, 50009
- Reclutamiento
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85704
- Retirado
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Reclutamiento
- Research Site
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- Research Site
-
Irvine, California, Estados Unidos, 92618
- Reclutamiento
- Research Site
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Research Site
-
Palo Alto, California, Estados Unidos, 94304
- Retirado
- Research Site
-
San Francisco, California, Estados Unidos, 94143
- Aún no reclutando
- Research Site
-
Sylmar, California, Estados Unidos, 91342
- Retirado
- Research Site
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Reclutamiento
- Research Site
-
Miami, Florida, Estados Unidos, 33133
- Aún no reclutando
- Research Site
-
Miami Beach, Florida, Estados Unidos, 33140
- Reclutamiento
- Research Site
-
Orlando, Florida, Estados Unidos, 32804
- Reclutamiento
- Research Site
-
St. Petersburg, Florida, Estados Unidos, 33705
- Reclutamiento
- Research Site
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Research Site
-
West Palm Beach, Florida, Estados Unidos, 33401
- Reclutamiento
- Research Site
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Retirado
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Retirado
- Research Site
-
-
Illinois
-
Arlington Heights, Illinois, Estados Unidos, 60005
- Reclutamiento
- Research Site
-
Evanston, Illinois, Estados Unidos, 60201
- Reclutamiento
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, Estados Unidos, 71103
- Reclutamiento
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Reclutamiento
- Research Site
-
Silver Spring, Maryland, Estados Unidos, 20910
- Aún no reclutando
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Reclutamiento
- Research Site
-
Worcester, Massachusetts, Estados Unidos, 01655
- Retirado
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- Research Site
-
Detroit, Michigan, Estados Unidos, 48201
- Retirado
- Research Site
-
-
Minnesota
-
Marshall, Minnesota, Estados Unidos, 56258
- Reclutamiento
- Research Site
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- Research Site
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Research Site
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Reclutamiento
- Research Site
-
-
Missouri
-
Springfield, Missouri, Estados Unidos, 65804
- Reclutamiento
- Research Site
-
St Louis, Missouri, Estados Unidos, 63141
- Reclutamiento
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Retirado
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Reclutamiento
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Reclutamiento
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Retirado
- Research Site
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Research Site
-
New York, New York, Estados Unidos, 10075
- Retirado
- Research Site
-
New York, New York, Estados Unidos, 10016
- Retirado
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Reclutamiento
- Research Site
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Reclutamiento
- Research Site
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45220
- Reclutamiento
- Research Site
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Aún no reclutando
- Research Site
-
Tulsa, Oklahoma, Estados Unidos, 74134
- Retirado
- Research Site
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Reclutamiento
- Research Site
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Retirado
- Research Site
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Aún no reclutando
- Research Site
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Reclutamiento
- Research Site
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- Reclutamiento
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Reclutamiento
- Research Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78758
- Reclutamiento
- Research Site
-
Fort Worth, Texas, Estados Unidos, 76104
- Reclutamiento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Research Site
-
San Antonio, Texas, Estados Unidos, 78240
- Reclutamiento
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Reclutamiento
- Research Site
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Research Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98133
- Retirado
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- Research Site
-
-
-
-
-
Helsinki, Finlandia, 00290
- Reclutamiento
- Research Site
-
Oulu, Finlandia, 90029
- Reclutamiento
- Research Site
-
Tampere, Finlandia, 33520
- Reclutamiento
- Research Site
-
Turku, Finlandia, 20521
- Reclutamiento
- Research Site
-
-
-
-
-
Besançon, Francia, 25030
- Retirado
- Research Site
-
Bordeaux, Francia, 33076
- Reclutamiento
- Research Site
-
Caen, Francia, 14076
- Reclutamiento
- Research Site
-
Clermont-Ferrand, Francia, 63000
- Reclutamiento
- Research Site
-
Lyon, Francia, 69373
- Reclutamiento
- Research Site
-
Montpellier, Francia, 34298
- Reclutamiento
- Research Site
-
Nice, Francia, 06100
- Reclutamiento
- Research Site
-
Paris, Francia, 75015
- Reclutamiento
- Research Site
-
Plérin, Francia, 22190
- Reclutamiento
- Research Site
-
Poitiers, Francia, 86021
- Reclutamiento
- Research Site
-
Saint-Herblain, Francia, 44805
- Retirado
- Research Site
-
Toulouse, Francia, 31059
- Reclutamiento
- Research Site
-
-
-
-
-
Budapest, Hungría, 1122
- Reclutamiento
- Research Site
-
Budapest, Hungría, 1088
- Reclutamiento
- Research Site
-
Debrecen, Hungría, 4032
- Reclutamiento
- Research Site
-
-
-
-
-
Catania, Italia, 95100
- Reclutamiento
- Research Site
-
Florence, Italia, 50134
- Reclutamiento
- Research Site
-
Milan, Italia, 20141
- Reclutamiento
- Research Site
-
Milan, Italia, 20159
- Reclutamiento
- Research Site
-
Milan, Italia, 20162
- Reclutamiento
- Research Site
-
Monza, Italia, 20900
- Reclutamiento
- Research Site
-
Naples, Italia, 80131
- Reclutamiento
- Research Site
-
Reggio Emilia, Italia, 422122
- Reclutamiento
- Research Site
-
Roma, Italia, 00144
- Reclutamiento
- Research Site
-
Rome, Italia, 00168
- Reclutamiento
- Research Site
-
Torino, Italia, 10128
- Reclutamiento
- Research Site
-
Turin, Italia, 10128
- Reclutamiento
- Research Site
-
-
-
-
-
Akashi-shi, Japón, 673-8558
- Retirado
- Research Site
-
Ginowan-shi, Japón, 901-2725
- Reclutamiento
- Research Site
-
Hidaka-shi, Japón, 350-1298
- Reclutamiento
- Research Site
-
Isehara-shi, Japón, 259-1193
- Reclutamiento
- Research Site
-
Kashiwa, Japón, 227-8577
- Reclutamiento
- Research Site
-
Kashiwa-shi, Japón, 277-8567
- Reclutamiento
- Research Site
-
Kobe, Japón, 650-0047
- Reclutamiento
- Research Site
-
Kurume-shi, Japón, 830-0011
- Reclutamiento
- Research Site
-
Kōtoku, Japón, 135-8550
- Reclutamiento
- Research Site
-
Matsuyama, Japón, 791-0280
- Reclutamiento
- Research Site
-
Morioka, Japón, 028-3695
- Reclutamiento
- Research Site
-
Nagoya, Japón, 464-8681
- Reclutamiento
- Research Site
-
Niigata, Japón, 951-8520
- Reclutamiento
- Research Site
-
Osaka, Japón, 541-8567
- Reclutamiento
- Research Site
-
Ota-shi, Japón, 373-8550
- Reclutamiento
- Research Site
-
Sapporo, Japón, 060-8638
- Reclutamiento
- Research Site
-
Sendai, Japón, 980-8574
- Reclutamiento
- Research Site
-
Shinjuku-ku, Japón, 160-8582
- Reclutamiento
- Research Site
-
Sunto-gun, Japón, 411-8777
- Reclutamiento
- Research Site
-
Tokyo, Japón, 104-0045
- Reclutamiento
- Research Site
-
Yokohama, Japón, 241-8515
- Reclutamiento
- Research Site
-
-
-
-
-
Oslo, Noruega, 0379
- Reclutamiento
- Research Site
-
Stavanger, Noruega, 4011
- Reclutamiento
- Research Site
-
-
-
-
-
Amsterdam, Países Bajos, 1066CX
- Retirado
- Research Site
-
Leiden, Países Bajos, 2333 ZA
- Retirado
- Research Site
-
Nijmegen, Países Bajos, 6525 GA
- Retirado
- Research Site
-
Rotterdam, Países Bajos, 3015 GD
- Retirado
- Research Site
-
-
-
-
-
Bialystok, Polonia, 15-027
- Reclutamiento
- Research Site
-
Gdansk, Polonia, 80-214
- Reclutamiento
- Research Site
-
Lodz, Polonia, 93-338
- Reclutamiento
- Research Site
-
Poznan, Polonia, 60-569
- Reclutamiento
- Research Site
-
Siedlce, Polonia, 08-110
- Reclutamiento
- Research Site
-
Szczecin, Polonia, 70-111
- Reclutamiento
- Research Site
-
-
-
-
-
Beijing, Porcelana, 100142
- Reclutamiento
- Research Site
-
Changchun, Porcelana, 130021
- Reclutamiento
- Research Site
-
Changsha, Porcelana, 410013
- Reclutamiento
- Research Site
-
Chengdu, Porcelana, 610041
- Reclutamiento
- Research Site
-
Chengdu, Porcelana, 610072
- Reclutamiento
- Research Site
-
Chongqing, Porcelana, 400030
- Reclutamiento
- Research Site
-
Fuzhou, Porcelana, 350001
- Reclutamiento
- Research Site
-
Fuzhou, Porcelana, 350014
- Reclutamiento
- Research Site
-
Guangzhou, Porcelana, 510120
- Reclutamiento
- Research Site
-
Guangzhou, Porcelana, 510080
- Reclutamiento
- Research Site
-
Guangzhou, Porcelana, 510060
- Reclutamiento
- Research Site
-
Haikou, Porcelana, 570311
- Reclutamiento
- Research Site
-
Hangzhou, Porcelana, 310022
- Reclutamiento
- Research Site
-
Harbin, Porcelana, 150049
- Reclutamiento
- Research Site
-
Hefei, Porcelana, 230001
- Reclutamiento
- Research Site
-
Jinan, Porcelana, 250117
- Reclutamiento
- Research Site
-
Jinan, Porcelana, 250021
- Reclutamiento
- Research Site
-
Jining, Porcelana, 272029
- Reclutamiento
- Research Site
-
Kunming, Porcelana, 650118
- Reclutamiento
- Research Site
-
Lanzhou, Porcelana, 730030
- Retirado
- Research Site
-
Nanchang, Porcelana, 330006
- Retirado
- Research Site
-
Nanning, Porcelana, 530021
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200011
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 201318
- Reclutamiento
- Research Site
-
Shantou, Porcelana
- Reclutamiento
- Research Site
-
Shenyang, Porcelana, 110042
- Reclutamiento
- Research Site
-
Shenyang, Porcelana, 110004
- Reclutamiento
- Research Site
-
Taiyuan, Porcelana, 030001
- Reclutamiento
- Research Site
-
Tianjin, Porcelana, 300060
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430022
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430000
- Reclutamiento
- Research Site
-
Xi'an, Porcelana, 710061
- Reclutamiento
- Research Site
-
Xuzhou, Porcelana, 221009
- Reclutamiento
- Research Site
-
Yibin, Porcelana, 610500
- Retirado
- Research Site
-
Ürümqi, Porcelana, 830000
- Retirado
- Research Site
-
-
-
-
-
Bath, Reino Unido, BA1 3NG
- Reclutamiento
- Research Site
-
Cambridge, Reino Unido, CB2 0QQ
- Reclutamiento
- Research Site
-
Leeds, Reino Unido, LS9 7TF
- Reclutamiento
- Research Site
-
London, Reino Unido, EC1A 7BE
- Reclutamiento
- Research Site
-
Manchester, Reino Unido, M20 4BX
- Reclutamiento
- Research Site
-
Northwood, Reino Unido, HA6 2RN
- Reclutamiento
- Research Site
-
Taunton, Reino Unido, TA1 5DA
- Reclutamiento
- Research Site
-
-
-
-
-
Linköping, Suecia, 581 85
- Reclutamiento
- Research Site
-
Lund, Suecia, 22185
- Reclutamiento
- Research Site
-
Stockholm, Suecia, 17164
- Reclutamiento
- Research Site
-
Uppsala, Suecia, 751 85
- Reclutamiento
- Research Site
-
-
-
-
-
Frauenfeld, Suiza, 8501
- Retirado
- Research Site
-
Liestal, Suiza, CH- 4410
- Reclutamiento
- Research Site
-
Sankt Gallen, Suiza, 9007
- Reclutamiento
- Research Site
-
Zurich, Suiza, 8091
- Reclutamiento
- Research Site
-
-
-
-
-
Changhua, Taiwán, 500
- Reclutamiento
- Research Site
-
Kaohsiung City, Taiwán, 81362
- Reclutamiento
- Research Site
-
New Taipei City, Taiwán, 220
- Reclutamiento
- Research Site
-
Taichung, Taiwán, 40705
- Reclutamiento
- Research Site
-
Tainan, Taiwán, 704
- Reclutamiento
- Research Site
-
Taipei, Taiwán, 10449
- Reclutamiento
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
-
≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations.
-
Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed).
-
Participant must have primary advanced disease (Stage III/IV) or recurrent endometrial cancer and meet at least one of the following criteria:
- Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment.
- Primary Stage IV (per FIGO 2023) disease regardless of presence of measurable disease at baseline.
- Recurrent disease regardless of presence of measurable disease at baseline.
-
Endometrial cancer with HER2 IHC expression of 3+ or 2+ by prospective central testing.
-
Endometrial cancer that is determined pMMR by prospective central testing.
-
Provision of an adequate FFPE tumor tissue sample for central HER2, MMR, and PD-L1 IHC testing.
-
Prior therapy:
- No prior chemotherapy for the treatment of EC, except for one prior line of adjuvant/ neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if completed ≥ 6 months prior to signature of the main ICF. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed.
- No prior exposure to antibody-drug conjugates or immune checkpoint inhibitors
- Participants may have received prior radiation therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
- Participants may have received prior hormonal therapy for the treatment of endometrial cancer. Adequate treatment washout period is required
-
ECOG 0-1.
-
Left ventricular ejection fraction ≥ 50% within 28 days before randomization.
-
Adequate organ and bone marrow function within 14 days before randomization.
-
The participant is not considered a candidate for curative therapy in the judgment of the investigator.
Key Exclusion Criteria:
-
Any severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardize compliance with the protocol.
-
Active or ongoing serious chronic gastrointestinal conditions associated with diarrhea, primary immunodeficiency, or non-infectious skin disease requiring systemic treatment.
-
Active or prior documented autoimmune or inflammatory disorders requiring chronic systemic treatment with the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs.
-
History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
-
Lung criteria:
- Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, etc.).
- Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening.
- Prior pneumonectomy (complete).
-
History of myocardial infarction or unstable angina within 6 months before randomization, or symptomatic congestive heart failure (NYHA Class II to IV), clinically significant arrhythmia, uncontrolled hypertension, cardiomyopathy of any etiology or history of myocarditis.
-
History of organ transplant or allogeneic stem cell transplant.
-
Spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases may be included in the study.
-
Evidence of any of the following infections:
- Active tuberculosis
- HIV infection that is not well controlled.
- Active hepatitis B or C infection.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: T-DXd + Rilvegostomig
T-DXd IV Q3W plus rilvegostomig IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first. |
Experimental therapy by intravenous infusion
Otros nombres:
Experimental therapy by intravenous infusion |
|
Experimental: Arm B: T-DXd + Pembrolizumab
T-DXd IV Q3W plus pembrolizumab IV Q3W. Treatment will continue until objective disease progression according to RECIST v1.1 as assessed by the Investigator and confirmed by BICR or until other discontinuation criteria is met, whichever occurs first. |
Experimental therapy by intravenous infusion
Otros nombres:
Immunotherapy by intravenous infusion
Otros nombres:
|
|
Comparador activo: Arm C: Carboplatin + Paclitaxel + Pembrolizumab
Carboplatin, paclitaxel and pembrolizumab administered Q3W for 6 cycles, followed by maintenance with pembrolizumab IV Q6W for 14 cycles. Treatment with pembrolizumab will continue for up to 20 total cycles (approximately 24 months, accounting for combination and maintenance phases) or until other discontinuation criteria is met, whichever occurs first. At the discretion of the investigator, participants may continue to receive carboplatin, paclitaxel and pembrolizumab Q3W for up to 10 cycles. Docetaxel can be used as an alternative to paclitaxel for participants who had a hypersensitivity reaction to paclitaxel with a failed rechallenge (or not amenable to rechallenge), according to the investigator's clinical judgment. |
Immunotherapy by intravenous infusion
Otros nombres:
Standard of Care (SoC) chemotherapy by intravenous infusion
Otros nombres:
Standard of Care (SoC) chemotherapy by intravenous infusion
Otros nombres:
Standard of Care (SoC) chemotherapy by intravenous infusion
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS), as assessed by BICR
Periodo de tiempo: Until progression or death due to any cause (assessed up to approximately 45 months).
|
Defined as time from randomization until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause. |
Until progression or death due to any cause (assessed up to approximately 45 months).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Until the date of death due to any cause (assessed up to approximately 70 months).
|
Defined as the time from randomization until the date of death due to any cause. |
Until the date of death due to any cause (assessed up to approximately 70 months).
|
|
Progression Free Survival (PFS) as assessed by the investigator
Periodo de tiempo: Until progression or death due to any cause (assessed up to approximately 70 months).
|
PFS by investigator has the same attributes as estimand of PFS by BICR except tumor assessment is by the investigator. |
Until progression or death due to any cause (assessed up to approximately 70 months).
|
|
Time from randomization to second progression or death (PFS2)
Periodo de tiempo: Until the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death (assessed up to approximately 70 months).
|
PFS2 will be defined as the time from randomization to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death. |
Until the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death (assessed up to approximately 70 months).
|
|
Objective response rate (ORR), as assessed by BICR and investigator
Periodo de tiempo: Until progression or the starting of subsequent anticancer therapy (assessed up to approximately 45 months).
|
ORR as assessed and confirmed by BICR is defined as the proportion of participants who have a complete response (CR) or partial response (PR), as determined and confirmed by BICR. ORR as assessed and confirmed by the investigator has the same attributes as estimand of ORR by BICR except tumor assessment per the investigator. |
Until progression or the starting of subsequent anticancer therapy (assessed up to approximately 45 months).
|
|
Duration of response (DoR), as assessed by BICR and investigator
Periodo de tiempo: Until progression or death due to any cause (assessed up to approximately 45 months).
|
DoR as assessed by BICR will be defined as the time from the date of first documented response of confirmed responders until date of documented progression per RECIST 1.1, or death due to any cause. DoR as assessed by the investigator has the same attributes as estimand of DoR by BICR except tumor assessment per the investigator. |
Until progression or death due to any cause (assessed up to approximately 45 months).
|
|
Safety and tolerability
Periodo de tiempo: Safety is assessed until the 90 days (+7) after the last dose (assessed up to approximately 70 months).
|
Safety and tolerability will be evaluated in terms of AEs/serious AEs (SAEs), AESI, vital signs, clinical safety laboratory assessments, ECG and ECHO/MUGA scan results. |
Safety is assessed until the 90 days (+7) after the last dose (assessed up to approximately 70 months).
|
|
Pharmacokinetics of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig
Periodo de tiempo: Up to safety follow-up period (assessed up to approximately 45 months).
|
Serum concentration of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig. |
Up to safety follow-up period (assessed up to approximately 45 months).
|
|
Immunogenicity of T- DXd and rilvegostomig
Periodo de tiempo: Up to safety follow-up period (assessed up to approximately 45 months).
|
Presence of ADAs for T-DXd or rilvegostomig. |
Up to safety follow-up period (assessed up to approximately 45 months).
|
|
Patient-reported tolerability
Periodo de tiempo: Until progression as assessed by BICR (assessed up to approximately 45 months).
|
Patient-reported tolerability will be described among participants, as treated, using the following outcomes:
|
Until progression as assessed by BICR (assessed up to approximately 45 months).
|
|
Progression-free survival (PFS) according to MMR status to determine the clinical utility of a MMR diagnostic test
Periodo de tiempo: Through completion of study, assessed up to approximately 70 months.
|
PFS is defined as time from randomization until progression per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause. |
Through completion of study, assessed up to approximately 70 months.
|
|
Overall survival (OS) according to MMR status to determine the clinical utility of a MMR diagnostic test
Periodo de tiempo: Through completion of study, assessed up to approximately 70 months.
|
OS defined as the time from randomization until the date of death due to any cause. |
Through completion of study, assessed up to approximately 70 months.
|
|
Progression-free survival (PFS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test
Periodo de tiempo: Through completion of study, assessed up to approximately 70 months.
|
PFS is defined as time from randomization until progression per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by BICR, or death due to any cause. |
Through completion of study, assessed up to approximately 70 months.
|
|
Overall survival (OS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test
Periodo de tiempo: Through completion of study, assessed up to approximately 70 months.
|
OS is defined as the time from randomization until the date of death due to any cause. |
Through completion of study, assessed up to approximately 70 months.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Pembrolizumab
- Carboplatino
- Carcinoma endometrial
- Cáncer endometrial
- Muerte celular programada-1 (PD1, PD-1)
- Paclitaxel
- TÍGITO
- Inhibidor del punto de control inmunitario
- Cáncer uterino
- DS-8201a
- T-DXd
- Trastuzumab deruxtecán
- pMMR
- Rilvegostomig
- Receptor 2 del factor de crecimiento epidérmico humano (HER2)
- Conjugado de fármaco antiher2-anticuerpo (ADC)
- Destiny-endometrial01
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias Genitales Femeninas
- Neoplasias Endometriales
- Neoplasias Uterinas
- Enfermedad de Parkinson 4, cuerpo autosómico dominante de Lewy
- Químicos orgánicos
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Docetaxel
- Carboplatino
- Paclitaxel
- pembrolizumab
- trastuzumab deruxtecan
Otros números de identificación del estudio
- D781DC00001
- 2023-508056-19-00 (Identificador de registro: CTIS (EU))
- GOG-3098 (Otro identificador: Gynecologic Oncology Group Foundation)
- ENGOT-EN24 (Otro identificador: European Network for Gynaecological Oncological Trial groups)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .